

Anthera Pharmaceuticals Announces Presentations of Sollpura Data at the North American Cystic Fibrosis Conference

November 2, 2017

HAYWARD, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that data from the SOLUTION, Phase 3 clinical study of Sollpura (liprotamase) and an additional non-clinical study will be presented at the 31st annual North American Cystic Fibrosis Conference (NACFC) in Indianapolis from November 2-4.

A total of three presentations will highlight data evaluating the use of Sollpura for the treatment of exocrine pancreatic insufficiency.

All three posters will be presented during Poster Session 1 on Thursday, November 2, between 11:15am – 1:45pm.

Poster 208: Comparison of biologically-manufactured liprotamase, a non-porcine pancreatic enzyme replacement therapy, to porcine enzyme product (pancrelipase) on fat and protein absorption in subjects with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis
Presented by Dr Michael Konstan, Case Western Reserve University School of Medicine and Rainbow Babies and Children's Hospital, Pediatrics, Cleveland, Ohio; lead primary investigator of the SOLUTION clinical study

Poster 221: Effects of gastric acid suppressants on response to liprotamase, a non-porcine pancreatic enzyme replacement therapy in patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis
Presented by Dr Michael Wilschanski, Hadassah Medical Center, Jerusalem, Israel

Poster 626: Liprotamase improves nutritional and health status in pigs with surgically-induced exocrine pancreatic insufficiency
Presented by Jaroslaw Wolinski, PhD, DSc, The Kielanowski Institute of Animal Physiology and Nutrition, Polish Academy of Sciences, Jab?onna, Poland

All NACFC abstracts are available on the conference website at <https://www.nacconference.org>.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and IgA nephropathy. Additional information on the Company can be found at www.anthera.com.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including but not limited to those set forth in Anthera's public filings with the SEC, including Anthera's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT:

Investor Relations of Anthera Pharmaceuticals, Inc.
ir@anthera.com

For Media Inquiries:
Frannie Marmorstein, 305-567-0821
frannie.marmorstein@rbcommunications.com

www.twitter.com/antherapharma
<https://www.facebook.com/antherapharma/>
<https://www.linkedin.com/company/anthera-pharmaceuticals>

Source: Anthera Pharmaceuticals, Inc.